Archive for April, 2009

Genetics and Addiction

Tuesday, April 28th, 2009

Just swing a cat these days and you’ll hit a new paper on genetics in Addiction. This is how they usually go: “We got together a big group of people with addiction to a chemical and another group that doesn’t have addiction to that chemical. We measured single nucleotide polymorphisms (SNPs) of genes that we think may have to do with addiction to the drug and this is what we found.” The results are either positive or negative for a correlation between the group with addiction and a particular SNP. These studies are very interesting and usually end up in a lot of press response that “the gene for (fill in the blank) addiction has been found.” The problem is that there are a lot of problems with this common methodology and the studies don’t mean what everyone thinks they mean.

The first problem is selection of the subjects. Currently DSM IV divides Addiction (which it calls Substance Dependence) into different diagnoses based on the drug used. So when scientists go to select subjects they select for those with a particular DSM diagnosis. The problem is that a lot of things other than the illness go into what drug the person comes to treatment with. Culture, availability and family upbringing all have to do with what drug is used and confound the genetic biology of the illness. For instance, a good percentage of people that come to treatment for “opioid dependence” have a strong history of cocaine use. Many of these will say that they didn’t like cocaine much and didn’t use it much, but other’s will say that cocaine worked well to relieve the symptoms of Addiction, in fact it worked better than opioids, however the cocaine crash was horrible and opioids last longer. So biologically what’s the difference between someone who is using opioids because that’s the best drug and someone who is using opioids because it’s their second best drug and they don’t like the first because of a pharmacokinetic rather than reward phenomenon? We’ll never know if they both get stuck in the same group of opioid addicts for a study.

Another problem is the reporting of the SNPs that are associated with the addicted group without any knowledge of what the SNP does to the active protein. That, in itself, isn’t bad but most of these studies never hold out the possibility of the effect going both ways. It’s pretty easy to assume that if a receptor is mutated it doesn’t work as well as the normal, but that’s not a good assumption. There are many examples of polymorphisms where the mutation causes over activity rather than underactivity of the protein. For instance there is a commonly studied mutation of the COMT enzyme that breaks down dopamine. The people who did the original work didn’t say this but many people assumed that this meant that the mutation kept COMT from working and therefore there was too much dopamine causing enhanced reward and leading to drug use and abuse. However, it turned out that the COMT enzyme actually works better with this polymorphism and so one would suppose a lower dopamine level leading to underactivation and craving. The difference here may seem small but it leads to two entirely different world views of addiction: that drugs cause reward via dopamine and we should block the effect to stop drug use or that people who are addicted have a generally lower dopamine tone and need dopamine increasing treatments to stop using.

The third problem is that of using a SNP by itself. Increasingly, and I’m glad, studies are dropping associations with single SNPs for associations with haplotypes. A haplotype is a grouping of SNPs. For instance lets say that Gene A has 4 SNPs (1,2,3, and 4) each can be either A or G. The haplotypes would be groups of these combinations such as AAGA or AGGA. This is important because one SNP may change the way the protein works and another change it back or cause some other effect. So if we only look at the first one we’ll see an association that may not be there or fail to see one that is.

So, simply, these three problems stand in our way. Of course, there are more problems, but I’m keeping this simple. We don’t know the function of the SNPs we’re measuring and without that we don’t know what to do with the information. We don’t have biological divisions that make sense when testing subjects so we aren’t going to find out the biologically important information. And lastly we should focus on the thing that actually works, the whole protein, not a single amino acid in the protein and therefore we should study hapoltypes more so than single SNPs.

When these three problems get more attention it will become much more common that genetic studies inform treatment for illnesses, including Addiction. People like me who spend all day treating addicts will be much happier when this day comes. So all you genetic researchers out there, get too it. I need a whole lot more informing.

© Howard C Wetsman MD FASAM

Prevent What?

Saturday, April 18th, 2009

I recently had the opportunity to listen to some thoughts by the leaders of Addiction Medicine about policies of prevention. They all seemed very learned and several quoted important studies, but what seemed missing was an answer to a basic question, “Prevent what?”

Were they talking of preventing illegal substance abuse in order to decrease lawlessness? Or did they have a public health interest in decreasing the use of alcohol, tobacco and other drugs because it’s not healthy to drink an industrial solvent or take neurotoxins? Did they want to decrease the overuse of substances on special occasions by normal people that leads to so much difficulty at British soccer games and on American roads at New Year? Was it Substance Abuse, the chronic maladaptive use of substances in spite of social difficulty, that they wanted to prevent? Could it have been Substance Dependence, an illness characterized by repetitive, compulsive maladaptive use in spite of physical or psychological consequences? Or, finally, were they wanting to prevent Addiction, a largely genetic brain illness with symptoms that occur both with and without drug use or compulsive use of rewarding behaviors?

The answer is, “Yes.”

They wanted to do prevention for all of that, which is laudable, but doomed to failure. It is doomed because they do not sufficiently see the difference between the multiple conditions listed above. It’s all of a piece to our society, and we want to prevent all of it with one prevention program. We use the terms Addiction, Substance Dependence, and Substance Abuse interchangeably with “the drug problem,” “drunk driving” and “drug related crime.” A single effort cannot work against a complex set of social, medical, and societal problems.

For instance let’s prevent diabetes. Do we want to prevent insulin dependent diabetes? Juvenile diabetes? How about diabetes caused by genetic malformations of prancreatic cells? Or diabetes caused by 30 years of too much rich food and no exercise? This is without taking into account preventing the effects of diabetes such as loss of eyesight and heart disease. Would you ever imagine you could prevent all of these with a single effort? The medical people behind prevention in most other chronic illnesses seem to find it of extreme importance to understand the multiple causes of the illness. They differentiate between primary prevention (prevention of the illness), secondary prevention (prevention of illness progression) and tertiary prevention (prevention of complications of the illness). Further, most people working in prevention of medical illness think it’s important to understand first what the core phenomenon of the disease is and what are the epiphenomena that seem to be associated with it. That’s important because if you don’t figure out this difference you end up trying to prevent the epiphenomena instead of the illness. It’s like preventing frequency of urination through a bladder medicine when the person is making more urine because of the diabetes. It might keep them from needing a bathroom as frequently, but it’s not prevention of the illness.

Almost all of these things that are true of people working to prevent medical diseases aren’t true in our field. In addition we have the added twist of having legality caught up in the mix; it’s like what the diabetes prevention people would have to deal with if the government made sugar illegal. Before we get serious about prevention (and we should) we need to understand what we’re trying to prevent.

We’ve long tried to prevent illegal drug use by punishing those who are caught and attempting to control access to the drugs. This would be the right approach if demand were elastic; that is, if people chose to use and could chose not to if the expected cost was too high. What we have instead is a long history of “drug epidemics” rotating through the various drugs. It’s like the game at the arcade where you try to hit all the gophers coming out of holes. As you hit one another pops up. Make alcohol illegal and smoking goes up. Get people to stop smoking and drinking so much and overeating becomes a problem.

I’m an Addiction Medicine physician, and other than a general public health interest in people not taking poisons or killing themselves and others in cars, my interest in this area is limited to primary, secondary, and tertiary prevention of Addiction. Notice I’m not saying prevention of drug use by addicts; that’s not sufficient. I want to prevent the disease along with all the symptoms and all the suffering, much of which is independent of drug use.

It has been widely supposed that preventing drug use can prevent addiction. I’ve seen no evidence of that. I’ve had a longstanding challenge to my colleagues for someone to show me even one research paper that shows you can prevent a large percentage of addiction by preventing drug use. If I were rich, I’d offer prize money for it. As it is, no one has come forward to show me one to shut me up. Before you get excited and send me a paper, please note I’m not interested in preventing alcoholism or any other ism related to a specific drug or behavior. You need to show me that the primary symptoms of addiction, the things my patients complain of, can be prevented by preventing drug use.

While I’m waiting for the research to prove me wrong, it would probably be a good idea to focus on defining what it is we’re trying to prevent so we will know how. Throwing money down the same hole we’ve been using for 50 years doesn’t sound like a plan for success.

© Howard C Wetsman MD FASAM

A Self-centering Illness

Wednesday, April 15th, 2009

I am often faced with the self-centeredness of people with addiction, as are most people who deal with addicts. It immediately grates on one’s sense of what the interaction should be and often creates a defensiveness in us that keeps us from hearing what the person with addiction is actually saying. Society looks at this self-centeredness and sees willful selfish behavior, not illness.

So the question is, is the self-centeredness of an addict a mark of unconscionable behavior, a personality trait that predisposes to addiction or a result of the biology of addiction. The first two have been long debated as they are the only two that were seen as possibilities without understanding the underlying biology of the illness. Without modern scientific understanding (that is, left with only society’s observations or the observational definitions created by psychiatry) there is no way to understand an original biology that causes addiction and that could account for behaviors that are often seen with the illness but have not been seen to have the same cause. So, any biological model of addiction must explain self-centeredness. I think it does.

If we accept that the biology of addiction is often created genetically or environmentally early in life, and we accept that this biology is best characterized by the effects of a lowered dopamine tone in the reward center, we can begin to understand that the illness begins before the first drug and has a discrete set of symptoms other than drug use. The train of effects of not having enough dopamine tone in the reward center is that there is not a signal of wellbeing to a part of the brain’s cortex (insula) that is set up to calculate the self of “wellness.” It is related to another part of the cortex (cingulate)  that seems to calculate the need for behavioral reaction to the lack of “wellness.” This circuit seems to function in its natural state, not for determining when we need more cocaine, but to tell us when we should act to protect ourselves. It is, in short, a survival mechanism.

As all survival mechanisms, it is unconscious and automatic. It drives behavior at a deep level regardless of what we “think” we ought to do. It should be noted that this circuit doesn’t drive us to ask for help, it drives us to act in our own self interest. Survival mechanisms wouldn’t do much good for the organism if they required help from other organisms.

In most people this circuit only drives behavior in dire circumstances such as famine, war, natural disaster, etc. But in some who have a lowered dopamine tone, this circuit will be active all the time. If the lowered dopamine tone starts early and is lifelong, this drive to act to protect oneself will become ingrained in the person’s repertoire of behaviors. They will act, most of the time, as if their wellbeing depended on their own ability to solve the situation or problem. They will, by necessity, center their behavior and attention on their own needs as those needs are signaled as paramount by their biology.

This hypothesis is testable, I believe. If I am correct we will see more self-centeredness in people who develop the symptoms of addiction early than in those who develop it late in life. Nora Volkow’s work with dopamine receptor density shows that aging lowers dopamine signaling in the reward circuits and suggests that the risk of addiction rises, not declines, with age. While the biology would be the same, the lifelong character on which that biology is superimposed will be different. This is true to the point that we might not even recognize that the elderly lady alcoholic has the same disease as the man who has been drinking since he was 10. In my practice it has become relatively easy to identify those who have had lifelong symptoms and those whose symptoms started late in life. Additionally, genetic testing is coming available that could give an objective measure of genetic causes of low dopamine symptoms though I think this will be less correlated with self-centeredness than early symptom production in general because the symptoms are largely monolithic while the genetics is quite varied.

I look forward to someone proving me wrong. That’s how science works, and it will mean that we now have a better idea than mine.

© Howard C Wetsman MD FASAM

Dr Outcomes Goes to Washington

Monday, April 13th, 2009

In an inspired choice, President Obama has named Dr Thomas McLellan as the Deputy Drug Czar (there’s a more official title, but saying this is easier) in charge of decreasing drug demand. Dr McLellan has become known for being a pioneer in quantifying outcomes in treatment and has aided this work with several innovations that allow all in our field to measure our progress. He’s brought up some pretty controversial ideas including compensation by outcome which would really stand our industry on its head.

As Dr McLellan’s brief is to decrease demand, he is the most important person in the office. Decreasing demand for drugs by treating Addiction is key to this effort and treatment must result in more than employment for the treaters. Dr McLellan’s tenure will be sure to shake things up and get us all thinking about what we do and why. I can’t wait.

Perhaps while he’s at it he’ll take a swing at the idea that an Addiction Medicine Specialist should be limited in the number of patients he or she treats with a certain medication. Would we ever tell an endocrinologist that he can only have 100 patients on insulin?

Best of luck, Tom. I’m glad you’re there.

© Howard C Wetsman MD FASAM